Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay

Ling, Zhi‐Qiang; Qi, Chunjian; Lu, Xiaoxiao; Qian, Lijuan; Gu, Linhui; Zheng, Zhong; Zhou, Qiang; Wang, Shi; Fang, Xian-Hua; Yang, Zhixing; Yin, Jia; Mao, Weimin

doi:10.1038/aps.2011.195

Cited by 15 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kyse-140, a human oesophageal squamous carcinoma cell line, and cancer cell primary cultures both expressed P2Y 2 receptors, which mediated inhibition of growth [451]. Using the ATPtumour chemosensitivity assay, heterogeneity of chemosensitivity in oesophageal cancer has been reported [444]. Neuroendocrine tumours are a heterogeneous group of neoplasms originating from enteric chromaffin cells and these tumours express A 2A …”

Section: Injurymentioning

confidence: 99%

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Burnstock

2013

Purinergic Signalling

View full text Add to dashboard Cite

Purinergic signalling plays major roles in the physiology and pathophysiology of digestive organs. Adenosine 5′-triphosphate (ATP), together with nitric oxide and vasoactive intestinal peptide, is a cotransmitter in nonadrenergic, non-cholinergic inhibitory neuromuscular transmission. P2X and P2Y receptors are widely expressed in myenteric and submucous enteric plexuses and participate in sympathetic transmission and neuromodulation involved in enteric reflex activities, as well as influencing gastric and intestinal epithelial secretion and vascular activities. Involvement of purinergic signalling has been identified in a variety of diseases, including inflammatory bowel disease, ischaemia, diabetes and cancer. Purinergic mechanosensory transduction forms the basis of enteric nociception, where ATP released from mucosal epithelial cells by distension activates nociceptive subepithelial primary afferent sensory fibres expressing P2X3 receptors to send messages to the pain centres in the central nervous system via interneurons in the spinal cord. Purinergic signalling is also involved in salivary gland and bile duct secretion.

show abstract

Section: Injurymentioning

confidence: 99%

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Burnstock

2013

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Drug sensitivity data obtained from 2D-based cell culture systems are often ambiguous due to the variations observed in the morphology, growth pattern, and gene expression of tumour cells in a 3D matrix. In addition, compared to the planar cell culture, 3D cell culture has been shown to more accurately influence cell morphology, gene/protein expression, signal transduction, proliferation, migration, and drug tolerance (Asphahani et al, 2011; Arias et al, 2010; Gurski et al, 2010; Nyga et al, 2011; Hong et al, 2012; Ning et al, 2011; Ling et al, 2012; Forestier et al, 2012). Different drug sensitivities were observed for cells grown in 3D culture configurations compared with a 2D monolayer model (Serebriiskii et al, 2008; Doillon et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

A microfluidic platform for drug screening in a 3D cancer microenvironment

Pandya

Dhingra

Prabhakar

et al. 2017

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Development of resistance to chemotherapy treatments is a major challenge in the battle against cancer. Although a vast repertoire of chemotherapeutics is currently available for treating cancer, a technique for rapidly identifying the right drug based on the chemo-resistivity of the cancer cells is not available and it currently takes weeks to months to evaluate the response of cancer patients to a drug. A sensitive, low-cost diagnostic assay capable of rapidly evaluating the effect of a series of drugs on cancer cells can significantly change the paradigm in cancer treatment management. Integration of microfluidics and electrical sensing modality in a 3D tumour microenvironment may provide a powerful platform to tackle this issue. Here, we report a 3D microfluidic platform that could be potentially used for a real-time deterministic analysis of the success rate of a chemotherapeutic drug in less than 12 h. The platform (66 mm × 50 mm; L×W) is integrated with the microsensors (interdigitated gold electrodes with width and spacing 10 μm) that can measure the change in the electrical response of cancer cells seeded in a 3D extra cellular matrix when a chemotherapeutic drug is flown next to the matrix. B16-F10 mouse melanoma, 4T1 mouse breast cancer, and DU 145 human prostate cancer cells were used as clinical models. The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12 h for drug-susceptible and drug tolerant breast cancer cells compared to control were 50552 ± 144 Ω and 28786 ± 233 Ω, respectively, while that of drug-susceptible melanoma cells were 40197 ± 222 Ω and 4069 ± 79 Ω, respectively. In case of prostate cancer the impedance change between susceptible and resistant cells were 8971 ± 1515 Ω and 3281 ± 429 Ω, respectively, which demonstrated that the microfluidic platform was capable of delineating drug susceptible cells, drug tolerant, and drug resistant cells in less than 12 h.

show abstract

“…Chemosensitivity was assessed in OEC tumor tissue samples using an ATP-TCA kit (Huzhou Haichuang Biotech Co., Ltd., Huzhou, Zhejiang, China), containing serum-free complete assay medium (CAM), digestive enzymes and luciferin-luciferase reagent. ATP-TCA tests were performed according to previously described methods (18,19). Specimens (1 cm 3 ) from solid tumors were obtained during surgery and cut into smaller fragments (1 mm 3 ), which were then dissociated to prepare suspensions of single cells by incubation in 5-10 ml sterile digestive enzyme reagent for 2-3 h at 37˚C in a 5% CO 2 incubator.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay

Zhang

2015

Oncology Letters

View full text Add to dashboard Cite

Abstract.Ovarian cancer has a poor prognosis, primarily due to the heterogeneity in chemosensitivity among patients. In the present study, this heterogeneity was evaluated in ovarian epithelial cancer (OEC) using an in vitro adenosine triphosphate tumor chemosensitivity assay (ATP-TCA). Specimens were collected from 80 patients who underwent cytoreductive surgery. Viable ovarian cancer cells obtained from malignant tissues were tested for sensitivity to paclitaxel (PTX), carboplatin (CBP), topotecan (TPT), gemcitabine (GEM), docetaxel (TXT), etoposide, bleomycin and 4-hydroperoxycyclophosphamide using ATP-TCA. The sensitivity, specificity, positive predictive value and negative predictive value for the clinical chemotherapy sensitivity of OEC were 88.6, 77.8, 83 and 84.8%, respectively. PTX demonstrated the highest sensitivity of all agents tested (82.5% in all specimens, 85.7% in recurrent specimens), followed by CBP (58.8 and 60.7%, respectively). The sensitivities to PTX and docetaxel (P<0.001) were correlated, in addition to those of CBP, TPT and GEM (P<0.001). Early-stage (I/II) and high-to mildly-differentiated OEC specimens revealed a lower chemosensitivity than advanced-stage (III) or low-differentiated specimens, respectively. The present study indicated that ATP-TCA is an effective method for guiding the choice of chemotherapy drugs. Notable heterogeneity of chemosensitivity was observed in the OEC specimens.

show abstract

Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay

Cited by 15 publications

References 28 publications

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

A microfluidic platform for drug screening in a 3D cancer microenvironment

Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay

Contact Info

Product

Resources

About